• Actuate Therapeutics reported Phase 2 elraglusib data in first-line metastatic pancreatic cancer at the 2026 ASCO Annual Meeting.
• Post-hoc analyses indicated longer survival in selected biomarker-defined patients receiving elraglusib with standard chemotherapy versus chemotherapy alone.
• A separate Phase 2 study suggested added clinical benefit when elraglusib was combined with FOLFIRINOX, with responses appearing deeper and more durable.
• Safety appeared manageable across regimens, supporting further development and potential positioning of elraglusib as a combination backbone therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010700PRIMZONEFULLFEED9729360) on June 01, 2026, and is solely responsible for the information contained therein.